Table 2.

Phenotypes and percentages of immune-cell subsets in TDLNs of patients with cervical cancer

Target populationPhenotypeLN+LNP
T cells
 CD4+ T cellsCD3+CD4+61.07 ± 4.4079.62 ± 2.14<0.001
 CD8+ T cellsCD3+CD8+32.45 ± 4.9818.31 ± 2.160.006
 Double-negative T cellsCD3+CD4CD84.24 ± 0.591.51 ± 0.16<0.001
 Double-positive T cellsCD3+CD4+CD8+2.25 ± 0.950.55 ± 0.080.002
 Activated T cellsCD3+CD4+HLA-DR+37.24 ± 9.4316.25 ± 1.880.014
CD3+CD8+HLA-DR+49.47 ± 15.5220.73 ± 3.800.151
CD3+CD4+ICOS+28.00 ± 8.7813.87 ± 2.540.190
CD3+CD8+ICOS+9.57 ± 4.054.58 ± 0.570.600
 Inhibited T cellsCD3+CD4+CTLA-4+27.01 ± 4.1315.07 ± 1.19<0.001
CD3+CD8+CTLA-4+9.16 ± 3.314.77 ± 0.660.058
CD3+CD4+PD-1+22.11 ± 6.094.43 ± 0.44<0.001
CD3+CD8+PD-1+22.90 ± 8.674.10 ± 0.800.001
 Naïve T cellsCD3+CD4+CD27+CD45RA+39.32 ± 12.6249.50 ± 4.010.336
CD3+CD8+CD27+CD45RA+42.22 ± 22.2463.74 ± 6.040.202
 Memory-like T cellsCD3+CD4+CD45RO+62.14 ± 12.5636.64 ± 4.290.152
CD3+CD8+CD45RO+58.46 ± 17.0024.21 ± 4.390.011
CD3+CD8+CD45RACD27+54.25 ± 21.3929.39 ± 5.070.099
 Effector-like T cellsCD3+CD8+CD45RA+CD270.98 ± 0.571.33 ± 0.290.801
 CD4+ TregsCD3+CD4+CD25hiFoxp3+10.08 ± 2.272.19 ± 0.36<0.001
 CD8+ TregsCD3+CD8+CD25hiFoxp3+1.36 ± 0.630.42 ± 0.090.029
DC subsets
 DDCsCD11chiCD1aint0.15 ± 0.050.02 ± 0.010.019
 LCsCD11cintCD1ahi0.01 ± 0.000.00 ± 0.00<0.001
 CD14+ (APC)CD1aCD11c+CD14+1.08 ± 0.340.19 ± 0.040.049
 CD14 (LNDC)CD1aCD11c+CD140.50 ± 0.060.34 ± 0.070.032
 Plasmacytoid DCsCD123+BDCA-2+0.59 ± 0.190.58 ± 0.180.653
MDSCs
 Monocytic MDSCsLinCD33+CD14+HLA-DR−/low0.09 ± 0.030.01 ± 0.010.010
 Granulocytic MDSCsCD11b+CD33+CD15+0.50 ± 0.410.17 ± 0.090.660

NOTE: Data are expressed as mean ± SEM.

Abbreviations: DDC, dermal-like dendritic cell; LC, Langerhans cell; LNDC, lymph node–resident dendritic cell.